Capital Investment Advisory Services LLC decreased its holdings in Abbott Laboratories (NYSE: ABT) by 44.2% during the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,546 shares of the healthcare product maker's stock after selling 12,335 shares during the quarter. Capital Investment Advisory
ABN Amro Investment Solutions raised its holdings in Abbott Laboratories (NYSE: ABT) by 21.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 111,702 shares of the healthcare product maker's stock after buying an additional 19,480 shares during the quarter. ABN Amro Investment
Abbott said on Thursday it reached a $670 million settlement with three law firms to resolve legal claims by 2,000 people who alleged harms relating to the company's specialty formulas for preterm infants.
Agreements will resolve the Gill case and claims involving approximately 2,000 other individuals Abbott and the medical community stand by the safety of preterm infant formulas Regulators and medical professionals recognize that these products are safe and necessary, and there is no reliable scientific evidence that they cause necrotizing enterocolitis ABBOTT PARK, Ill., Aug. 20, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals relating to the company's specialty formulas for preterm infants.
Greenleaf Trust trimmed its holdings in Abbott Laboratories (NYSE: ABT) by 11.7% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 54,832 shares of the healthcare product maker's stock after selling 7,261 shares during the quarter. Greenleaf Trust's holdings in Abbott Laboratories were
ABT's Medical Devices growth is fueled by electrophysiology, expanding CGM adoption and a cardiovascular pipeline extending into 2029 and beyond.
Abbott Laboratories remains a high-quality, diversified healthcare leader with renewed momentum across nutrition, diagnostics, and medical devices. ABT's Q2 2026 saw accelerating 4.8% YoY sales growth and broad-based profitability improvement, with adjusted gross margin up 100 bps to 58.0%. Growth catalysts include the Exact Sciences acquisition for cancer diagnostics, innovative PFA solutions in electrophysiology, and a nutrition turnaround.
Abbott Laboratories remains a buy, with accelerating earnings growth, margin expansion, and robust segment performance following Q2's double beat and guidance raise. ABT's Exact Sciences acquisition strengthens its long-term growth runway, supporting a raised EPS outlook and 10.4% CAGR over the next six years. Despite recent price appreciation, ABT trades below its 5-year forward P/E average, offering a 2.5% yield and a potential 37% upside to a $151 price target.
Envestnet Portfolio Solutions Inc. cut its holdings in shares of Abbott Laboratories (NYSE: ABT) by 12.1% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 53,774 shares of the healthcare product maker's stock after selling 7,427 shares during the period. Envestnet
Farmers and Merchants Investments Inc. lifted its stake in shares of Abbott Laboratories (NYSE: ABT) by 2.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 182,692 shares of the healthcare product maker's stock after acquiring an additional 5,167 shares
